Clinical Trials Browser

INDUSTRY × Recurrence × Paclitaxel × Clear all

Breast Neoplasms, Recurrence

NCT03981796 2025-09-03

RUBY

Phase 3 Active not recruiting

785 enrolled 2 FDA

Neoplasms, Recurrence

NCT04868708 2025-03-04

A Study of AK104（ an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in Recurrent or Metastatic Cervical Cancer

Phase 2 Completed

50 enrolled

Gynecologic

Diabetes Mellitus, Insulin-Dependent, 12, Uterine Cervical Neoplasms, Recurrence

NCT04921527 2024-10-18

CHIPRO

Phase 3 Recruiting

454 enrolled

Gynecologic

Ovarian Neoplasms, Recurrence

NCT03326102 2024-02-16

OPERA

Phase 2 Completed

72 enrolled

Breast

Breast Neoplasms, Recurrence

NCT02855944 2023-06-09

ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients

Phase 3 Completed

349 enrolled 29 charts

Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms, Recurrence

NCT05798819 2023-04-05

A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer

Phase 3 Not yet recruiting

424 enrolled

Recurrence

NCT05715840 2023-02-08

Efficacy and Safety Study of First-line Treatment With SG001 Plus Chemotherapy ± Bevacizumab Versus Placebo Plus Chemotherapy ±Bevacizumab for Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)

Phase 3 Not yet recruiting

368 enrolled

Recurrence

NCT00479765 2022-06-22

A Phase 1 / 2 Dose Escalation Study of Locally-Administered OncoGel™ in Subjects With Recurrent Glioma

Phase 1/2 Terminated

4 enrolled 5 charts

CNS

Brain Neoplasms, Glioblastoma, Glioma, Neoplasms, Recurrence

NCT03901118 2021-03-19

Chiauranib in Combination With Chemotherapy in Patients With Ovarian Cancer

Phase 2 Completed

47 enrolled

Gynecologic

Ovarian Neoplasms, Recurrence

NCT02625623 2020-11-24

Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)

Phase 3 Completed

371 enrolled 18 charts

Gastrointestinal

Recurrence, Stomach Neoplasms

NCT02322281 2019-08-14

TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy

Phase 3 Terminated

149 enrolled 17 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms, Recurrence

NCT01852292 2018-07-24

Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy

Phase 2 Terminated

157 enrolled 22 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis, Recurrence

NCT03026881 2017-03-07

A Study of Fluzoparib Given in Combination With Apatinib and Paclitaxel in Gastric Cancer Patients

Phase 1 Unknown

24 enrolled

Gastrointestinal

Recurrence, Stomach Neoplasms

NCT02107378 2016-11-30

Efficacy of DCVAC/OvCa Plus Standard of Care in Relapsed Platinum Resistant Epithelial Ovarian Carcinoma

Phase 2 Terminated

22 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Recurrence

NCT01447706 2016-05-12

A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers

Phase 2 Completed

223 enrolled 10 charts

Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Recurrence

NCT02435186 2015-05-06

p53 Gene in Treatment of Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer

Phase 2 Unknown

100 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms, Recurrence

NCT01166542 2014-11-05

Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers

Phase 3 Completed

167 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Neoplasm Metastasis, Recurrence

NCT00448305 2012-01-05

EndoTAG-1 in Triple Receptor Negative Breast Cancer Patients

Phase 2 Completed

143 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis, Recurrence

Clinical Trials

OPTIMAL

RUBY

A Study of AK104（ an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in Recurrent or Metastatic Cervical Cancer

CHIPRO

OPERA

ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients

A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer

Efficacy and Safety Study of First-line Treatment With SG001 Plus Chemotherapy ± Bevacizumab Versus Placebo Plus Chemotherapy ±Bevacizumab for Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)

A Phase 1 / 2 Dose Escalation Study of Locally-Administered OncoGel™ in Subjects With Recurrent Glioma

Chiauranib in Combination With Chemotherapy in Patients With Ovarian Cancer

Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)

TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy

Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy

A Study of Fluzoparib Given in Combination With Apatinib and Paclitaxel in Gastric Cancer Patients

Efficacy of DCVAC/OvCa Plus Standard of Care in Relapsed Platinum Resistant Epithelial Ovarian Carcinoma

A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers

p53 Gene in Treatment of Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer

Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers

EndoTAG-1 in Triple Receptor Negative Breast Cancer Patients